Jack C Yalowich PhD

Jack C Yalowich PhD
ProfessorCollege of Pharmacyyalowich.1@osu.edu
532 Parks Hall 500 W 12th Avenue Columbus Ohio 43210
Phone:614-688-5980Fax: 614-292-9083
  • Translational Therapeutics

Research Description

Dr. Yalowich's recent studies are focused on understanding the mechanisms by which the clinically effective anticancer agent etoposide (VP-16), a phenolic compound, and the environmental carcinogen, benzene, can cause therapy-related acute myelogenous leukemia (t-AML). The central testable hypothesis is that redox cycling of VP-16 and phenolic benzene metabolites initiated by myeloperoxidase (MPO) in bone marrow precursors amplifies the genotoxicity and carcinogenicity of these compounds via enhanced inhibition/poisoning of DNA topoisomerase II. Nutritional antioxidants such as vitamin C and vitamin E homologs are under investigation as a mechanism-based chemoprevention strategy to eliminate VP-16- and benzene-induced AML by reducing production of MPO-dependent free radical and electrophilic metabolites. The long-term goal of these studies is to increase the clinical efficacy of VP-16 in the treatment of cancer, and to prevent benzene leukemogenesis.

Current Publications

  • Ren Y, Lantvit DD, Deng Y, Kanagasabai R, Gallucci JC, Ninh TN, Chai HB, Soejarto DD, Fuchs JR, Yalowich JC, Yu J, Swanson SM, Kinghorn ADPotent Cytotoxic Arylnaphthalene Lignan Lactones from Phyllanthus poilanei.J Nat Prod 77 1494-504 6/27/2014

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) 300 W. 10th Ave. Columbus, OH 43210 Phone: 1-800-293-5066 | Email: jamesline@osumc.edu